Scientech Research’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-676
Closed -$269K – 463
2025
Q4
$269K Sell
676
-3,196
-83% -$1.41M 0.17% 223
2025
Q3
$1.77M Buy
+3,872
New +$1.58M 0.62% 6
2025
Q1
– Sell
-2,280
Closed -$537K – 558
2024
Q4
$537K Buy
+2,280
New +$600K 0.15% 270
2024
Q2
– Sell
-2,688
Closed -$402K – 574
2024
Q1
$402K Buy
+2,688
New +$448K 0.21% 216

Other funds holding ALNY

Scientech Research's ALNY Position: Q1 2026 in Review

Scientech Research sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 676 shares — an estimated $269K sold.

Scientech Research first reported a position in ALNY in Q1 2024 and held it in 4 quarters. The position peaked at $1.77M in Q3 2025. 799 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Scientech Research reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Scientech Research sold 676 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $269K.
  • Scientech Research first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Scientech Research's Alnylam Pharmaceuticals position peaked at $1.77M in Q3 2025.
  • 799 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Scientech Research's 13F filing for Q1 2026, filed 15 May 2026.